What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
Josep M. Llovet focuses on Hepatocellular carcinoma, Internal medicine, Sorafenib, Carcinoma and Surgery.
Josep M. Llovet studies Liver cancer, a branch of Hepatocellular carcinoma.
His Internal medicine research includes elements of Gastroenterology and Oncology.
His study looks at the intersection of Sorafenib and topics like Regorafenib with Lenvatinib and Cabozantinib.
His Carcinoma research integrates issues from Percutaneous ethanol injection, Survival rate, Stage, Hepatectomy and Receiver operating characteristic.
His Surgery research focuses on Liver function and how it connects with Cirrhosis.
His most cited work include:
- Sorafenib in Advanced Hepatocellular Carcinoma (7596 citations)
- EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma (4279 citations)
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference (3541 citations)
What are the main themes of his work throughout his whole career to date?
Hepatocellular carcinoma, Internal medicine, Oncology, Cancer research and Sorafenib are his primary areas of study.
His Hepatocellular carcinoma research focuses on Surgery and how it relates to Liver function.
He focuses mostly in the field of Internal medicine, narrowing it down to topics relating to Gastroenterology and, in certain cases, Hepatitis C virus.
His Oncology research incorporates themes from Biomarker, Regorafenib and Disease.
Josep M. Llovet combines subjects such as Wnt signaling pathway, PI3K/AKT/mTOR pathway, Immune system and Bioinformatics with his study of Cancer research.
Josep M. Llovet interconnects Response Evaluation Criteria in Solid Tumors and Hazard ratio in the investigation of issues within Sorafenib.
He most often published in these fields:
- Hepatocellular carcinoma (109.73%)
- Internal medicine (72.06%)
- Oncology (48.04%)
What were the highlights of his more recent work (between 2018-2021)?
- Hepatocellular carcinoma (109.73%)
- Internal medicine (72.06%)
- Cancer research (57.77%)
In recent papers he was focusing on the following fields of study:
Josep M. Llovet mostly deals with Hepatocellular carcinoma, Internal medicine, Cancer research, Oncology and Liver cancer.
He has researched Hepatocellular carcinoma in several fields, including Biomarker, Cancer and Carcinoma.
In his research, Etiology is intimately related to Gastroenterology, which falls under the overarching field of Internal medicine.
His study in Cancer research is interdisciplinary in nature, drawing from both Wnt signaling pathway, Steatohepatitis, Epigenetics and Immune system.
His Oncology research is multidisciplinary, incorporating elements of Clinical endpoint and Disease.
His research integrates issues of Platelet, Transcriptome and ARID1A in his study of Liver cancer.
Between 2018 and 2021, his most popular works were:
- Hepatocellular carcinoma. (1254 citations)
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (410 citations)
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (410 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Josep M. Llovet focuses on Hepatocellular carcinoma, Internal medicine, Oncology, Cancer research and Carcinoma.
His studies deal with areas such as Cancer and General surgery as well as Hepatocellular carcinoma.
Sorafenib and Clinical endpoint are the subjects of his Internal medicine studies.
The study incorporates disciplines such as Biomarker, Advanced stage, Clinical trial and Disease in addition to Oncology.
In general Cancer research study, his work on Liver cancer often relates to the realm of CCL5, thereby connecting several areas of interest.
His work deals with themes such as Gene mutation, BCLC Stage, ARID1A, Tumor progression and Telomerase reverse transcriptase, which intersect with Carcinoma.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
